Lutathera

Should be used by physicians trained and experienced in radiopharmaceuticals. Handle with appropriate safety measures to minimize radiation exposure during and after Lutathera. Increased risk for cancer with long-term cumulative radiation exposure. Monitor closely for hypersensitivity reactions during and after infusion for a minimum of 2hrs in a setting where cardiopulmonary resuscitation medication/equipment are available. Discontinue infusion at 1^st signs/symptoms of a severe hypersensitivity reaction; permanently discontinue if Grade 3 or 4 reactions occur. Monitor CBCs, serum creatinine, CrCl, transaminases, bilirubin, serum albumin, and INR during therapy; withhold, reduce dose, or permanently discontinue based on severity of reaction. Advise patients to hydrate and urinate frequently before, on the day of, and the day after administration. Monitor for signs/symptoms of tumor-related hormonal disease (eg, flushing, diarrhea, hypotension, bronchoconstriction, others); give IV somatostatin analogues, fluids, corticosteroids, and electrolytes as indicated. Mild or moderate renal impairment: assess renal function more frequently. Severe hepatic or renal impairment (CrCl <30mL/min) or ESRD: not studied. Risk of infertility. Embryo-fetal toxicity. Advise to use effective contraception during and for 7 months (females of reproductive potential) or 4 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 2.5 months after the last dose).